Predictive markers for response to interferon therapy in patients with multiple sclerosis
- 25 March 2008
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 70 (13_part_2) , 1119-1127
Abstract
Background: Prolonged therapy with interferon β (IFNβ) often leads to the development of anti-IFNβ binding antibodies (BAbs). A subset of the BAbs is of a neutralizing nature (neutralizing antibodies, NAbs) and is associated with reduced clinical efficacy of therapy. Myxovirus-resistance-protein A (MxA) has proven to be a reliable biomarker of IFNβ bioactivity. We analyzed the prognostic value of MxA mRNA, NAbs, and BAbs on the risk of having a new relapse in IFNβ-treated patients. Methods: A 3-year study was conducted in 137 IFNβ-treated patients. Blood samples for BAbs, NAbs, and MxA mRNA measurements were taken after 12 ± 3 months of therapy. Analysis of relapse-free survival (RFS) was performed for all measures by using known thresholds, generating “positive” and “negative” groups. Also, time between sampling and following relapse and risk of new relapses were calculated. Results: The MxA-negative group showed poorer RFS rates than the MxA-positive group [p < 0.0001, hazard ratio (HR) = 2.87]. Likewise, the NAb-positive group showed poorer RFS rates than the NAb-negative group (p =0.0013; HR = 2.49). On the contrary, BAb measurement did not show a clear clinical significance. Conclusions: Findings indicate that measurements of both myxovirus-resistance-protein A (MxA) and neutralizing antibodies (NAbs) predict the risk of new relapses; however, the slightly stronger prognostic significance of MxA mRNA and the easier method for it measurement make MxA mRNA the preferred biomarker for monitoring interferon β (IFNβ)-treated patients. This information can be used to better tailor treatment to the individual patient with MS. GLOSSARY: BAb = binding antibody; CPE = cytopathic effect; EDSS = Expanded Disability Status Scale; GAPDH = glyceraldehyde phosphate dehydrogenase; HR = hazard ratio; IFN = interferon; MxA = myxovirus-resistance-protein A; NAb = neutralizing antibody; RFS = relapse-free survival; ROC = receiver operating characteristic; TRU = 10-fold reduction units.Keywords
This publication has 34 references indexed in Scilit:
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosisEuropean Journal of Neurology, 2005
- The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodiesJournal of Neuroimmunology, 2005
- Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodiesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPsBrain, 2004
- Assessment of different treatment failure criteria in a cohort of relapsing–remitting multiple sclerosis patients treated with interferon β: Implications for clinical trialsAnnals of Neurology, 2002
- Mechanisms for Regulation of Cellular Responsiveness to Human IFN- β 1aJournal of Interferon & Cytokine Research, 2002
- The Neutralization of Interferons by Antibody. II. Neutralizing Antibody Unitage and Its Relationship to Bioassay Sensitivity: The Tenfold Reduction UnitJournal of Interferon & Cytokine Research, 2001
- Development of Neutralizing Antibodies in Patients with Relapsing-Remitting Multiple Sclerosis Treated with IFN-β1aJournal of Interferon & Cytokine Research, 1998
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSISAnnals of the New York Academy of Sciences, 1965